We are pleased to announce that Translational Cancer Research (TCR) has attained its latest impact factor update for the 2022 citation year: 0.9 (Figure 1).
Figure 1. Journal Impact Factor of TCR
Translational Cancer Research (Transl Cancer Res, TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE) and PubMed/PubMed Central. TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards.
We strive to follow the best practices in publishing. The release of the journal’s latest impact factor is not only a significant achievement for the journal but also the recognition of its more significant scientific reach. Here, we would like to extend our heartfelt gratitude to all our editorial team members, guest editors, authors, and reviewers for their significant contributions.
We look forward to the continuous cooperation with all the individuals mentioned above and those who are interested in gland disease to bring more exciting content to readers in the coming future.
Editorial Office
Translational Cancer Research
June 30, 2023